TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

RI-AG03: Novel Drug Targets Tau Protein Hotspots, Showing Promise in Alzheimer's Research

8 months ago

• RI-AG03, a novel drug, simultaneously targets two critical hotspots on tau proteins, which are implicated in Alzheimer's disease progression. • Preclinical studies in fruit flies demonstrated that RI-AG03 suppressed brain cell degeneration and extended lifespan, with higher dosages yielding greater improvements. • The drug also showed efficacy in reducing tau protein clumping in human cells in vitro, suggesting potential for slowing the formation of tau tangles. • Researchers plan further studies in rodents, with the ultimate goal of launching clinical trials to assess RI-AG03's safety and efficacy in humans.